|Bid||0.00 x 2200|
|Ask||0.00 x 900|
|Day's Range||4.97 - 5.19|
|52 Week Range||4.23 - 37.99|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced medtech veteran Kevin Collins has joined the company as Chief Revenue Officer with global revenue responsibility.
Shares of Lucira Health (NASDAQ: LHDX) exploded out of the gate when the company made its stock market debut in February. Lucira Health's over-the-counter COVID-19 tests racked up millions of dollars in sales during the first three months of 2021, leading some investors to wonder if this beaten-down stock can bounce back.
EMERYVILLE, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will be participating in the William Blair 41st Annual Growth Stock Conference. Lucira Health’s management is scheduled to participate in the conference on Wednesday, June 2, 2021, at 10:40 a.m. PT / 1:40 p.m. ET. Interested parties can access the live and archived webcast at ir.lucirahealth.com. About Lucira HealthLucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira’s testing platform produces lab quality molecular testing in a single-use, consumer-friendly, palm size test kit powered by two AA batteries. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular tests results anywhere and anytime. The LUCIRA CHECK IT (OTC) and LUCIRA COVID-19 All-In-One (RX) Test Kits are designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. For more information, visit www.lucirahealth.com. Investor Contact Greg Chodaczek Investorrelations@lucirahealth.com347-620-7010 Media Contact Kevin Knight firstname.lastname@example.org 206-451-4823